Go to homepage
Shopping cart CAD$0.00*
Show all categories Chemoresistance Mechanisms in SK-OV-3 Ovarian Cancer Cells Back

Chemoresistance Mechanisms in SK-OV-3 Ovarian Cancer Cells

Chemoresistance remains the primary obstacle to successful treatment of advanced ovarian cancer, with the majority of patients eventually developing resistance to platinum-based therapy despite initial responses. At Cytion, we understand that elucidating the molecular mechanisms underlying this resistance is essential for developing strategies to overcome treatment failure. SK-OV-3 cells, with their intrinsic platinum resistance phenotype, serve as a premier model for studying chemoresistance mechanisms and identifying therapeutic approaches to restore drug sensitivity.

Key Takeaways

  • SK-OV-3 cells exhibit multi-factorial chemoresistance involving drug efflux, DNA repair, and apoptosis evasion
  • ABC transporter overexpression actively removes chemotherapeutic agents from cells
  • Enhanced DNA damage repair capacity enables survival following genotoxic insult
  • Pro-survival signaling through PI3K/AKT and NF-κB pathways promotes chemotherapy survival
  • Combination strategies targeting resistance mechanisms can restore drug sensitivity
Chemoresistance Mechanisms in SK-OV-3 Cells SK-OV-3 Platinum-Resistant Drug excluded Drug efflux Drug Efflux • P-gp (MDR1) • MRP1/ABCC1 • BCRP/ABCG2 Active drug removal reduces intracellular drug concentration DNA Repair • NER pathway ↑ • HR repair intact • ERCC1 overexpr. Efficient repair of platinum-DNA adducts Apoptosis Defects • p53 null status • BCL-2/BCL-XL ↑ • IAP overexpr. Resistance to apoptotic cell death signals Survival Signaling • PI3K/AKT active • NF-κB constitutive • HER2 amplified Pro-survival pathway activation blocks death Resistance Reversal Strategies • ABC transporter inhibitors (verapamil) • PI3K/AKT inhibitors + chemotherapy • BH3 mimetics (BCL-2 inhibitors) • PARP inhibitors (HR defect exploitation) • Epigenetic modulators (HDAC inhibitors) Resistance Assay Methods • IC50 determination (MTT/CellTiter-Glo) • Colony formation survival assays • Drug accumulation (flow cytometry) • DNA damage (γH2AX, Comet assay) • Apoptosis (Annexin V, caspase assays) © Cytion - Overcoming Ovarian Cancer Resistance

Molecular Basis of SK-OV-3 Platinum Resistance

SK-OV-3 cells exhibit intrinsic resistance to cisplatin and carboplatin, the cornerstone chemotherapeutic agents for ovarian cancer treatment. This resistance phenotype is multifactorial, arising from concurrent alterations in drug transport, DNA damage response, and cell death signaling pathways.

Our SK-OV-3 Cells (300342) demonstrate IC50 values for cisplatin approximately 5-10 fold higher than platinum-sensitive ovarian cancer lines, providing a robust model for studying resistance mechanisms and screening for sensitizing agents.

The loss of functional p53 in SK-OV-3 cells eliminates a critical mediator of DNA damage-induced apoptosis. Without p53-dependent cell cycle arrest and death signaling, cells can survive and continue proliferating despite accumulating DNA damage from platinum agents. This p53-null status also influences response to numerous other therapeutics and should be considered when interpreting drug response data.

Drug Efflux and Reduced Accumulation

ATP-binding cassette (ABC) transporters actively export chemotherapeutic agents from cells, reducing intracellular drug concentrations below cytotoxic thresholds. SK-OV-3 cells express multiple ABC transporters that contribute to their resistant phenotype.

P-glycoprotein (P-gp, MDR1, ABCB1) represents the prototypical drug efflux pump, transporting a broad range of substrates including taxanes and anthracyclines. While platinum agents are not classical P-gp substrates, other resistance-associated transporters including MRP2 (ABCC2) can export platinum-glutathione conjugates.

Drug accumulation assays using fluorescent substrates or radiolabeled compounds quantify the impact of efflux on intracellular drug levels. Flow cytometry with calcein-AM or rhodamine 123 provides functional readout of P-gp activity. Reduced platinum accumulation measured by atomic absorption spectroscopy correlates with resistance severity.

ABC transporter inhibitors can restore drug sensitivity by blocking efflux. First-generation inhibitors like verapamil and cyclosporine A demonstrated proof of concept, while newer agents with improved specificity and reduced toxicity continue development for clinical application.

Enhanced DNA Damage Repair Capacity

Platinum agents exert cytotoxicity primarily through formation of DNA adducts that block replication and transcription. Cells with enhanced capacity to recognize and repair these lesions can survive chemotherapy exposure that would be lethal to repair-deficient cells.

Nucleotide excision repair (NER) removes bulky DNA adducts including platinum-DNA crosslinks. ERCC1, a critical NER component, shows elevated expression in SK-OV-3 cells and correlates with platinum resistance. ERCC1 knockdown sensitizes resistant cells to platinum treatment, validating this mechanism.

Homologous recombination (HR) repair handles DNA double-strand breaks and interstrand crosslinks. Unlike BRCA-mutant ovarian cancers that lack functional HR, SK-OV-3 cells maintain intact HR capacity, enabling repair of platinum-induced damage. This HR proficiency, while contributing to resistance, can be therapeutically targeted using PARP inhibitors that create synthetic lethality in HR-deficient contexts.

DNA damage response markers including γH2AX (phosphorylated H2AX) provide readouts of damage induction and repair kinetics. SK-OV-3 cells show rapid resolution of γH2AX foci following platinum treatment, reflecting their efficient repair capacity.

Apoptosis Evasion and Pro-Survival Signaling

Even when DNA damage accumulates, cancer cells must execute apoptotic programs to die. SK-OV-3 cells exhibit multiple alterations that block apoptosis execution, enabling survival despite cellular damage.

BCL-2 family proteins regulate the intrinsic apoptotic pathway. SK-OV-3 cells overexpress anti-apoptotic members including BCL-2 and BCL-XL while showing reduced levels of pro-apoptotic BH3-only proteins. This imbalance prevents mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release, blocking caspase cascade activation.

The PI3K/AKT pathway provides potent pro-survival signaling in SK-OV-3 cells. Constitutive AKT activation phosphorylates and inactivates pro-apoptotic proteins including BAD and FOXO transcription factors. PI3K inhibitors sensitize SK-OV-3 cells to chemotherapy by relieving this survival signal.

HER2 amplification in SK-OV-3 cells drives activation of both PI3K/AKT and MAPK pathways. HER2-targeted therapies including trastuzumab and lapatinib show activity in SK-OV-3 models and synergize with chemotherapy in combination regimens.

Strategies for Overcoming Resistance

Rational combination therapies targeting specific resistance mechanisms can restore chemosensitivity in SK-OV-3 cells. Identifying the dominant resistance mechanism in a given context guides selection of appropriate sensitizing agents.

BH3 mimetics including venetoclax and navitoclax directly antagonize anti-apoptotic BCL-2 family proteins, lowering the apoptotic threshold. Combination with platinum or taxane chemotherapy shows synergy in SK-OV-3 models by enabling apoptosis execution.

PI3K/AKT pathway inhibitors block pro-survival signaling and enhance chemotherapy-induced apoptosis. Multiple PI3K inhibitors are in clinical development for ovarian cancer, with combination strategies showing promise.

Recommended Products for Chemoresistance Research:

This website uses cookies to ensure you get the best experience on our website... More information.
- Imprint

We have detected that you are in a different country or are using a different browser language than currently selected. Would you like to accept the suggested settings?

Close